Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Elranatamab-bcmm |
Trade Name | Elrexfio |
Synonyms | PF-06863135|PF06863135|PF 06863135 |
Drug Descriptions |
Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov). |
DrugClasses | CD3 Antibody 99 TNFRSF17 Antibody 20 |
CAS Registry Number | NA |
NCIT ID | C146860 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carfilzomib + Elranatamab-bcmm | Carfilzomib Elranatamab-bcmm | 0 | 1 |
Cevostamab + Elranatamab-bcmm | Cevostamab Elranatamab-bcmm | 0 | 1 |
Daratumumab + Elranatamab-bcmm | Daratumumab Elranatamab-bcmm | 0 | 1 |
Daratumumab + Elranatamab-bcmm + Lenalidomide | Daratumumab Elranatamab-bcmm Lenalidomide | 0 | 1 |
Elranatamab-bcmm | Elranatamab-bcmm | 0 | 13 |
Elranatamab-bcmm + Iberdomide | Elranatamab-bcmm Iberdomide | 0 | 1 |
Elranatamab-bcmm + Nirogacestat | Elranatamab-bcmm Nirogacestat | 0 | 1 |